Nifty
Sensex
:
:
12010.20
40342.67
113.40 (0.95%)
-201.70 (-0.50%)

Pharmaceuticals & Drugs

Rating :
49/99  (View)

BSE: 532660 | NSE: VIVIMEDLAB

15.25
-0.55 (-3.48%)
21-Oct-2020 | 3:04PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  15.60
  •  16.00
  •  15.20
  •  15.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  67287
  •  10.26
  •  23.35
  •  6.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 131.00
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 990.41
  • N/A
  • 0.27

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 32.79%
  • 5.95%
  • 40.31%
  • FII
  • DII
  • Others
  • 3.1%
  • 0.12%
  • 17.73%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.37
  • -0.96
  • -3.46

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.13
  • -5.31
  • -16.02

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.35
  • -4.45
  • -35.52

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.99
  • 4.00
  • 2.87

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.85
  • 0.75
  • 0.37

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.05
  • 7.94
  • 9.12

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
323
344
-6%
236
348
-32%
198
244
-19%
281
365
-23%
Expenses
276
303
-9%
256
327
-21%
207
207
0%
285
314
-10%
EBITDA
47
41
13%
-21
21
-
-9
37
-
-3
50
-
EBIDTM
14%
12%
-9%
6%
-4%
15%
-1%
14%
Other Income
2
1
43%
2
6
-60%
2
6
-67%
2
5
-51%
Interest
15
12
23%
15
13
15%
16
18
-6%
16
18
-11%
Depreciation
17
17
2%
17
16
9%
16
15
2%
17
20
-14%
PBT
16
13
22%
-50
-1
-
-39
10
-
-33
18
-
Tax
3
3
7%
10
-1
-
-7
-1
-
-7
0
-
PAT
13
10
27%
-61
0
-
-32
11
-
-26
18
-
PATM
4%
3%
-26%
0%
-16%
4%
-9%
5%
EPS
1.55
1.22
27%
-7.34
0.00
-
-3.87
1.31
-
-3.18
2.21
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
1,037
1,315
1,186
1,462
1,346
1,380
1,351
1,109
668
416
343
Net Sales Growth
-20%
11%
-19%
9%
-2%
2%
22%
66%
61%
21%
 
Cost Of Goods Sold
439
518
480
536
624
646
656
513
337
237
203
Gross Profit
598
797
706
926
722
734
695
596
331
179
140
GP Margin
58%
61%
60%
63%
54%
53%
51%
54%
50%
43%
41%
Total Expenditure
1,024
1,146
985
1,057
1,123
1,158
1,166
928
538
329
279
Power & Fuel Cost
-
43
35
35
38
47
51
44
22
11
8
% Of Sales
-
3%
3%
2%
3%
3%
4%
4%
3%
3%
2%
Employee Cost
-
242
198
190
177
184
163
50
32
20
22
% Of Sales
-
18%
17%
13%
13%
13%
12%
5%
5%
5%
6%
Manufacturing Exp.
-
217
177
175
167
179
182
230
92
32
20
% Of Sales
-
17%
15%
12%
12%
13%
14%
21%
14%
8%
6%
General & Admin Exp.
-
112
79
94
95
76
87
69
31
16
15
% Of Sales
-
8%
7%
6%
7%
6%
6%
6%
5%
4%
4%
Selling & Distn. Exp.
-
14
17
15
21
25
27
20
23
11
9
% Of Sales
-
1%
1%
1%
2%
2%
2%
2%
3%
3%
3%
Miscellaneous Exp.
-
0
1
12
0
0
0
0
0
2
9
% Of Sales
-
0%
0%
1%
0%
0%
0%
0%
0%
1%
0%
EBITDA
14
169
201
404
223
222
185
181
130
87
64
EBITDA Margin
1%
13%
17%
28%
17%
16%
14%
16%
20%
21%
19%
Other Income
9
34
24
8
24
8
36
26
3
1
7
Interest
62
70
82
68
85
86
67
50
28
22
23
Depreciation
67
67
56
58
61
66
66
59
27
10
9
PBT
-107
66
86
286
100
78
87
98
78
55
40
Tax
0
9
10
72
16
5
20
14
15
6
9
Tax Rate
0%
13%
11%
25%
16%
7%
24%
15%
19%
12%
22%
PAT
-106
57
78
214
84
72
66
84
63
49
31
PAT before Minority Interest
-106
57
76
214
84
72
66
84
63
49
31
Minority Interest
0
0
2
0
0
0
0
0
0
0
0
PAT Margin
-10%
4%
7%
15%
6%
5%
5%
8%
9%
12%
9%
PAT Growth
-371%
-26%
-64%
156%
16%
9%
-21%
32%
29%
57%
 
EPS
-12.84
6.92
9.40
25.81
10.09
8.69
8.01
10.08
7.62
5.89
3.74

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
944
1,226
734
585
559
560
509
475
197
145
Share Capital
342
342
16
80
80
80
80
145
10
10
Total Reserves
602
885
718
505
479
478
427
328
178
130
Non-Current Liabilities
490
357
504
561
538
533
450
361
148
251
Secured Loans
369
276
396
207
436
379
255
258
132
235
Unsecured Loans
56
49
57
51
47
41
42
53
0
1
Long Term Provisions
9
7
2
4
3
5
1
1
2
0
Current Liabilities
889
790
817
897
801
744
611
464
242
59
Trade Payables
294
202
179
167
189
190
166
157
44
42
Other Current Liabilities
227
148
180
286
176
139
116
41
5
0
Short Term Borrowings
332
385
381
408
389
375
301
233
175
0
Short Term Provisions
35
55
77
37
46
40
27
33
19
17
Total Liabilities
2,322
2,386
2,055
2,044
1,898
1,837
1,570
1,299
587
456
Net Block
965
1,035
879
814
813
808
709
595
264
255
Gross Block
1,157
1,129
916
1,663
1,599
1,526
1,330
1,167
813
289
Accumulated Depreciation
192
93
37
849
786
718
620
572
548
34
Non Current Assets
1,092
1,104
961
911
906
846
736
604
266
256
Capital Work in Progress
122
65
76
94
90
38
27
8
2
1
Non Current Investment
3
3
3
3
3
0
0
1
0
0
Long Term Loans & Adv.
2
0
3
0
0
0
0
0
0
0
Other Non Current Assets
0
0
0
0
0
0
0
0
0
0
Current Assets
1,231
1,282
1,094
1,133
992
971
815
647
315
194
Current Investments
0
0
0
0
0
0
0
0
0
0
Inventories
564
540
484
491
431
427
340
248
84
79
Sundry Debtors
356
275
200
326
330
348
308
222
128
94
Cash & Bank
95
99
55
31
27
35
24
36
11
6
Other Current Assets
216
30
23
12
204
162
143
141
92
15
Short Term Loans & Adv.
185
338
332
273
185
140
120
141
89
15
Net Current Assets
342
492
277
235
191
226
204
183
72
135
Total Assets
2,322
2,386
2,055
2,044
1,898
1,837
1,570
1,299
587
456

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
422
21
58
154
140
-118
90
45
24
55
PBT
66
86
286
100
78
87
98
78
55
40
Adjustment
134
136
124
102
111
101
80
55
32
31
Changes in Working Capital
237
-158
-316
-48
-48
-306
-94
-88
-64
6
Cash after chg. in Working capital
437
63
95
154
140
-118
84
45
24
76
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-15
-42
-37
0
0
0
6
0
0
0
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-89
-164
-68
-190
-107
-291
-170
-424
-72
-7
Net Fixed Assets
-16
39
-26
-7
-49
-17
-129
-149
-27
8
Net Investments
64
-64
142
0
-2
-132
-8
-84
0
-1
Others
-138
-138
-185
-183
-55
-143
-33
-192
-46
-14
Cash from Financing Activity
-338
186
35
41
-42
419
67
404
54
-59
Net Cash Inflow / Outflow
-5
44
25
4
-8
11
-12
25
5
-11
Opening Cash & Equivalents
99
55
31
27
35
24
36
11
6
17
Closing Cash & Equivalent
94
99
55
31
27
35
24
36
11
6

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
70
105
86
64
61
58
53
42
35
27
ROA
2%
3%
10%
4%
4%
4%
6%
7%
9%
7%
ROE
8%
10%
35%
16%
15%
15%
23%
27%
31%
28%
ROCE
7%
9%
22%
12%
11%
12%
14%
14%
18%
16%
Fixed Asset Turnover
1.15
1.16
1.13
0.82
0.88
0.95
0.89
0.67
0.76
1.26
Receivable days
88
73
66
89
90
89
87
95
97
87
Inventory Days
153
158
122
125
113
104
97
91
72
79
Payable days
80
71
61
60
57
57
63
65
48
42
Cash Conversion Cycle
161
160
127
154
146
135
121
121
121
125
Total Debt/Equity
1.05
0.69
1.45
1.63
1.81
1.66
1.36
1.33
1.70
1.77
Interest Cover
2
2
5
2
2
2
3
4
4
3

News Update


  • Vivimed Labs receives approvals for ophthalmic, oral liquid suspension products
    13th Oct 2020, 09:57 AM

    The company is expecting 5 more approvals in Ophthalmics and Oral solids in 04 CY 2020

    Read More
  • Vivimed Labs receives export order for supply of Favulous tablets
    6th Aug 2020, 09:00 AM

    Favulous tablets 200 mg is used for the treatment of mild to moderate cases of Covid-19

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.